Pharmaceuticals, Biotechnology and Life Sciences
Vivace Therapeutics, an oncology-focused portfolio-based drug discovery and development company is coming out of stealth with $40 million raised in Series A and B financings.
Novartises Rydapt has been approved by the FDA for the treatment of acute myeloid leukemia, and for treating adults with advanced systemic mastocytosis.
Sosei Group Corporation’s subsidiary Heptares Therapeutics got milestone payment from AstraZeneca for working together on an immuno-oncology project.
AstraZeneca’s trial treating relapsed ovarian cancer patients with olaparib met its primary endpoint, the company said Tuesday.
Bristol-Myers Squibb has entered into an ASR program with each of Morgan Stanley & Co. LLC and Goldman, Sachs & Co. to repurchase, in aggregate, $2 billion of Bristol-Myers Squibb’s common stock, and it has named three new directors.
Botswana will be a centert for southern and east Africa for hematology-oncology treatment, as it will get a new $100…
Onxeo, an oncology French-based focused drugmaker and a cancer researcher, the Institut Curie, have kicked off several cancer studies, to test the combination of radiotherapy, DNA repair inhibitors and immunotherapy.
A swedish oncology company Oasmia Pharmaceutical AB, which works on finding cancer cures for animals and humans, said it would move its veterinary assets to the United States.
Sareum Holdings, a drugmaker focused on cancer drugs on Monday announced cashing a $2.0 million milestone payment as part of the Chk1 licence agreement between its co-investment partner, the CRT Pioneer Fund, and Sierra Oncology, formerly known as ProNAi Therapeutics.
Clinigen Group has made a deal with Cumberland Pharmaceuticals to market another product in the US, this time an oncology drug Totect (dexrazoxane hydrochloride).